1. Home
  2. PLCE vs ACET Comparison

PLCE vs ACET Comparison

Compare PLCE & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

N/A

Current Price

$2.24

Market Cap

72.5M

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$9.11

Market Cap

79.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLCE
ACET
Founded
1969
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.5M
79.9M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
PLCE
ACET
Price
$2.24
$9.11
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$3.50
$48.33
AVG Volume (30 Days)
227.5K
80.8K
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
11.48
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$0.46
52 Week High
$9.56
$9.84

Technical Indicators

Market Signals
Indicator
PLCE
ACET
Relative Strength Index (RSI) 32.53 59.16
Support Level N/A $7.45
Resistance Level $2.92 $9.58
Average True Range (ATR) 0.16 0.51
MACD -0.01 0.03
Stochastic Oscillator 23.20 67.91

Price Performance

Historical Comparison
PLCE
ACET

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: